Arcus Biosciences (NYSE:RCUS) has seen its stock rating upgraded from “sell” to “hold” by analysts at Wall Street Zen. This change reflects a growing confidence in the company, which is focused on developing innovative cancer immunotherapies. The report, released on a recent Saturday, marks a shift in sentiment as other financial analysts also express optimism.
On the same day, Citigroup reaffirmed a “buy” rating on Arcus shares. This follows similar endorsements from UBS Group and Truist Financial, which set a price target of $30.00 and noted the potential for growth within the company. Wells Fargo & Company has placed a price target of $23.00 on the stock and assigned an “equal weight” rating, while Morgan Stanley adjusted its price objective to $20.00, down from $23.00.
Analysts have shown a mixed assessment of Arcus Biosciences, with seven rating the stock as a “buy,” three as a “hold,” and one as a “sell.” Data from MarketBeat.com indicates that the consensus rating for the company is “Moderate Buy,” with an average price target of $29.33.
Recent Financial Performance
Arcus Biosciences released its latest quarterly earnings on February 25. The company reported an earnings per share (EPS) of ($0.89), surpassing analysts’ expectations of ($1.11) by $0.22. Despite this positive report, the company faced challenges, including a negative return on equity of 65.77% and a net margin of 142.91%. Revenue for the quarter reached $33.00 million, which is significantly higher than the consensus estimate of $24.94 million. However, this figure represents an 8.3% decline compared to the previous year’s revenue.
Looking ahead, analysts predict that Arcus Biosciences will post an EPS of ($3.15) for the current fiscal year, indicating continued financial challenges.
Insider Transactions and Institutional Investments
Recent insider activity has also drawn attention. Chief Accounting Officer Alexander Azoy sold 4,343 shares on December 18 for an average price of $22.25, totaling approximately $96,631.75. Following this transaction, Azoy retained 18,531 shares valued at around $412,314.75, marking an 18.99% decrease in his holdings.
General Counsel Carolyn C. Tang also sold 6,810 shares on December 17 for an average price of $22.16, yielding approximately $150,909.60. After the sale, Tang directly owned 124,734 shares valued at around $2,764,105.44, reflecting a 5.18% reduction in her stake. In total, insiders sold 263,987 shares worth $6,025,620 in the last quarter, with insiders currently owning 9.60% of the company’s stock.
Institutional investors have also been active, with several firms adjusting their positions in Arcus Biosciences. T. Rowe Price Investment Management Inc. acquired a new stake valued at approximately $39,000 during the fourth quarter. Invesco Ltd. raised its holdings by 41.7%, now owning 414,365 shares worth $9,874,000 after purchasing an additional 121,961 shares.
Additionally, the State of Tennessee Department of Treasury raised its stake by 34.2%, owning 34,855 shares valued at around $831,000. Wellington Management Group LLP significantly increased its position by 309.4%, now holding 5,184,509 shares valued at $123,547,000. Collectively, institutional investors own approximately 92.89% of Arcus Biosciences’ stock.
Overall, the recent upgrades and financial performance highlight a complex but potentially promising landscape for Arcus Biosciences as it navigates the challenges of the biopharmaceutical industry. The company continues to focus on advancing its pipeline of cancer immunotherapy candidates, which may impact its future market position.
